Human immunodeficiency virus (HIV) is one of the global epidemics that afflicts human civilization and concerns people worldwide. It attacks the immune system in the human body, which is responsible for defending against diseases. Different strategies have been attempted in order to prevent HIV transmission. In this project, we aim to investigate a drug that can act as a novel entry inhibitor by capturing HIV virions.  The central hypothesis being tested is that multi-functional Phenylboronic acids (PBA) will interact with HIV-gp120 with high binding affinity. Consequently, it will prevent the viral protein from interacting with its natural receptor CD4. This strategy may lead to the discovery of the first PBA based HIV viral entry inhibitor since it is known to form boronic esters in the presence of cis-diols, like the ones found in carbohydrates, glycans and glycoproteins such as HIV-gp 120. We will present our synthetic scheme, synthetic results, <sup>11</sup>B NMR and FT-IR analysis. Our future goal is to perform biological testing, which is essentially composed of binding affinity determination of the nanoconjugate to HIV-gp120 and in-vitro cytotoxicity analysis on vaginal and macrophage cell lines.<br/>

Closomer-PBA derivative for HIV virion capture

256th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.